On March 31, 2023,
Mizuho
initiated coverage of Vigil Neuroscience with
a Buy recommendation.
Analyst Price Forecast Suggests 109.31% Upside
As of March 30, 2023,
the average one-year price target for Vigil Neuroscience is $20.91.
The forecasts range from a low of $13.13 to a high of $25.20.
The average price target represents an increase of 109.31% from its latest reported closing price of $9.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vigil Neuroscience
is $0MM.
The projected annual non-GAAP EPS
is -$2.36.
What are Large Shareholders Doing?
Atlas Venture Life Science Advisors
holds 5,837K shares
representing 16.38% ownership of the company.
No change in the last quarter.
Northpond Ventures
holds 4,214K shares
representing 11.82% ownership of the company.
No change in the last quarter.
Artal Group
holds 2,243K shares
representing 6.29% ownership of the company.
In it’s prior filing, the firm reported owning 2,286K shares, representing
a decrease
of 1.88%.
The firm
increased
its portfolio allocation in VIGL by 76.33% over the last quarter.
Citadel Advisors
holds 2,164K shares
representing 6.07% ownership of the company.
In it’s prior filing, the firm reported owning 2,166K shares, representing
a decrease
of 0.12%.
The firm
increased
its portfolio allocation in VIGL by 40.62% over the last quarter.
Deep Track Capital
holds 2,104K shares
representing 5.90% ownership of the company.
In it’s prior filing, the firm reported owning 2,363K shares, representing
a decrease
of 12.31%.
The firm
increased
its portfolio allocation in VIGL by 12.13% over the last quarter.
What is the Fund Sentiment?
There are 59 funds or institutions reporting positions in Vigil Neuroscience.
This is an increase
of
1
owner(s) or 1.72% in the last quarter.
Average portfolio weight of all funds dedicated to VIGL is 0.90%,
an increase
of 24.10%.
Total shares owned by institutions increased
in the last three months by 1.77% to 24,998K shares.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
